Jump to Navigation
Home

Main menu

  • Home
  • Latest Stories
  • Markets Map
  • Trends and Sentiments
  • Leading Topics
  • News Search
  • Comments and Analysis

Secondary menu

  • Latest News
  • Top Rated
  • Most Popular
  • Archive
  • About Us
  • Relief for Greece? The debt dilemma facing creditors
  • How will rising Treasury yields affect markets?
  • The Most Traditional Afternoon Teas In London
  • Trader: "Algos Still Think Bad News Will Be Good...
  • Amazon, the last of FANG, reports earnings Thursday. Here...
  • Facebook admits it did not read the terms of the app that...
  • Is New EU “Travel Authorisation” Another Brexit-Induced...
  • King Dimon - For Now | JPMorgan
  • Yes, Fundamentals Usually Appear Strong Prior To A Sell-...
  • Disney plays up local ties in China amid trade standoff

    Can Teva Win With The Big Pharma Playbook?

    Wed, 05/09/2012 - 15:43 EDT - Seeking Alpha
    • BIIB
    • NVS
    • SNY
    • Stephen Simpson
    • TEVA

    By Stephen Simpson:There's no question that Teva Pharmaceuticals (TEVA) rewarded long-term investors with years and years of growth as it became the world's largest generic drug manufacturer. The biopharma world has changed, though, and so has Teva. Now branded companies like Novartis (NVS) and Sanofi (SNY) are in generics, and generic companies like Teva are in branded drugs. And just for good measure, a few outliers like Endo Pharmaceuticals (ENDP) add devices to the mix, while others like Abbott (ABT) and Covidien (COV) look to split and spin-off their drug businesses.What's the point? Well, mostly that Teva probably has to start thinking more and more like Big Pharma if they want to continue to grow the business. It's hard to imagine that there's much buying left to do in the generic space (apart, perhaps, from a few select deals in specific markets), but there's plenty that the company could do inComplete Story »

    • Original article
    • Login to post comments

    Related

    • Is It Time To Buy Teva?

      ByShankar N:2012 has been a do-nothing year for Teva Pharmaceuticals TEVA. Its stock is still at the same place where it started the year and the 2010 peak of $64 seems like Mount Everest. The stock is trading at a forward P/E of 6.9 and it's definitely worth investigating. The Company

    • Big Pharma Embraces Branded Generics

      Jason Chew submits: It seems not a day goes by without talk of an innovation crisis in the pharmaceutical industry. On, October 25, the German consultancy, Roland Berger, released an article titled “Fight of Flight” stating 65% of companies surveyed believe that the pharmaceutical industry is facing a strategic crisis. As the patent cliff nears, it appears the majority of Big Pharmas have taken to the “flight” path.

    • Teva Beats Pfizer in Bid for Big Generics Maker

      The Burrill Report submits: Teva Pharmaceutical (TEVA) will pay about $5 billion for Germany's second largest generic drugs maker, Ratiopharm, beating out Pfizer's (PFE) bid and maintaining its rank as the world's top generics company by sales. Novartis (NVS) remains the world's second-biggest generics maker.

    • Endo International (ENDP) Replaces Covidien Plc To Join SandP 500

      Endo International plc (NASDAQ:ENDP) will be joining the S&P 500 Index, replacing Covidien Plc (NYSE:COV); the change will take place after trading closes January 26, S&P Dow Jones Indices said Wednesday.

    • Novartis: Diversification For Stability

      By Doolan Wesley:In an ever-evolving world of healthcare and medicine, society is always looking for advanced treatments to address their needs.

    • How to Profit From Health Care: Teva Pharmaceuticals

      Think Yield submits:With health care reform growing in political popularity, there will be an increase in demand for drugs, especially cheaper, generic ones. Teva’s (TEVA) undisputed dominance of the generic drug market assures profitability and earning growth in the future.

    • The Top 20 Global Pharmaceuticals by Sales

      David Hunkar submits: The table below lists the top 20 global drug companies based on sales in 2009:

    • Sanofi Finally on Road to Recovery

      Sanofi SA (ADR) (NYSE:SNY) is in exclusive talks with Boehringer Ingelheim GmbH over an asset swap valued at around $25 billion (22.8 billion euros). Under the potential deal, Sanofi would trade its animal health unit for Boehringer’s consumer-health operations.

    • Will Valeant Pharmaceuticals Acquisition Target Buy Sanofi SA Animal Health Unit?

      Sanofi SA (ADR) (NYSE:SNY) stock shed over 8% on Friday after the drug-maker warned of flat profit over the next two years and said it is considering selling its animal health and generic drugs businesses. Such a move would help the company to cut its expenses and focus on fewer markets, as per Sanofi CEO Oliver Brandicourt.

    • Pfizer Inc. (PFE) Looks For Other Acquisition Targets After Teva Pharmaceutical (TEVA) Rejection

      Pfizer Inc. (NYSE:PFE) is looking to acquire companies to contribute to its revenue growth, and the hunt has become rather aggressive after Israel-based Teva Pharmaceutical Industries Ltd (NYSE:TEVA) rejected the company’s acquisition offer, as per sources familiar with the matter. The financial details of the offer remain undisclosed.

    Latest

    Links 4/26/18
    Links 4/26/18
    Women have shared 8 ways they got over the insecurity of being cheated on — and some of the answers make a lot of sense
    Women have shared 8 ways they got over the...

    Markets Map

    Markets Map

    Follow Us

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS
    S&P 500: 2579.37 0.16% FTSE: 7487.96 -0.07% Nikk.: 22420.08 1.82% DAX: 13465.51 1.75% HSI: 28594.06 1.22% FX: EUR/GBP: 1.1401 USD/EUR: 1.1618 JPY/USD: 114.1510 Commodities: Gold: 1276.1000

    Bullfax.com - Market News & Analysis 2008-2011
    Contact Us | About Us | Terms & Conditions

    Follow Us on Facebook, Twitter, Google Plus and RSS LinkedIn Facebook Twitter Google Plus RSS .

    Secondary menu

    • Latest News
    • Top Rated
    • Most Popular
    • Archive
    • About Us